Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review.

Cheng-Hao TsengChao-Ming TsengJia-Ling WuYao-Chun HsuHashem B El-Serag

Published in: Journal of gastroenterology and hepatology (2020)

The residual risk of HCC remains during ETV/TDF treatment in CHB patients with cirrhosis but declines over time. Risk stratification is attainable by validated predictive scores.

Keyphrases

hepatitis b virus
acute lymphoblastic leukemia
stem cells
combination therapy
replacement therapy